Ailing Mallinckrodt's drug for rare, life-threatening renal condition clears pivotal study
Embattled Mallinckrodt — tarnished by a cloud of opioid litigation as well as its controversially expensive Acthar gel — will enjoy its sliver of optimism that comes with a positive pivotal trial.
The UK drugmaker on Thursday unveiled data from a late-stage trial testing the drug, terlipressin, in patients with a life-threatening, progressive rare complication of liver disease that triggers kidney failure called hepatorenal syndrome type 1 (HRS-1), which affects an estimated 30,000 to 40,000 in the United States each year, the company said, adding that patients face a poor prognosis, with a median survival time of less than two weeks and more than 80% mortality within three months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.